bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Drop in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 251,900 shares, a decrease of 36.5% from the January 31st total of 396,800 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily volume of 177,700 shares, the days-to-cover ratio is currently 1.4 days.

bioAffinity Technologies Stock Down 4.3 %

Shares of NASDAQ:BIAF opened at $0.50 on Friday. bioAffinity Technologies has a 1-year low of $0.46 and a 1-year high of $3.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The stock has a market cap of $7.79 million, a P/E ratio of -0.61 and a beta of 2.95. The firm has a fifty day moving average price of $0.79 and a 200 day moving average price of $1.26.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC boosted its stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.